Pfizer's corporate venturing unit invested in the pharmaceutical company along with New Enterprise Associates, Fidelity Biosciences, ProQuest Investments, Harris and Harris Group, and Rho Ventures.
Pfizer’s corporate venturing unit Pfizer Venture Investments (PVI) has helped pharmaceutical company Mersana Therapeutics raise $27m in Series A-1 funding in a round led by venture firm New Enterprise Associates (NEA).
Pfizer and NEA were joined by previous investors Fidelity Investments’ pharmaceutical investment arm Fidelity Biosciences, as well as venture firms ProQuest Investments, Harris and Harris Group, Rho Ventures.
The proceeds from the investment will be used to develop Mersana’s antibody-drug combinations by using its biodegradable-polymer system, called Fleximer, previously…
